Company news

Atea Pharmaceuticals, Inc. news in 2024

Atea Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

December 15, 2024

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

December 3, 2024

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

November 14, 2024

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 6, 2024

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

October 30, 2024

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

September 12, 2024

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

August 27, 2024

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 6, 2024

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

June 4, 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

May 21, 2024

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

May 6, 2024

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

April 28, 2024

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

March 26, 2024

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 27, 2024

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

February 20, 2024

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

January 7, 2024

Calls in 2024

Decks in 2024